Inovio Pharmaceuticals, Inc. (INO)
1.435
-0.02
(-1.71%)
USD |
NASDAQ |
Nov 13, 16:00
1.42
-0.02
(-1.05%)
After-Hours: 19:59
Inovio Pharmaceuticals Enterprise Value : 119.79M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 119.79M |
| November 11, 2026 | 121.44M |
| November 10, 2026 | 118.68M |
| November 09, 2026 | 125.29M |
| November 06, 2026 | 92.79M |
| November 05, 2026 | 118.68M |
| November 04, 2026 | 137.41M |
| November 03, 2026 | 141.82M |
| November 02, 2026 | 167.16M |
| October 30, 2026 | 25.29M |
| October 29, 2026 | 43.96M |
| October 28, 2026 | 61.23M |
| October 27, 2026 | 56.98M |
| October 26, 2026 | 54.76M |
| October 23, 2026 | 57.76M |
| October 22, 2026 | 51.35M |
| October 21, 2026 | 46.55M |
| October 20, 2026 | 70.20M |
| October 19, 2026 | 69.10M |
| October 16, 2026 | 68.01M |
| October 15, 2026 | 73.51M |
| October 14, 2026 | 67.56M |
| October 13, 2026 | 68.90M |
| October 12, 2026 | 80.67M |
| October 09, 2026 | 85.63M |
| Date | Value |
|---|---|
| October 08, 2026 | 79.02M |
| October 07, 2026 | 86.18M |
| October 06, 2026 | 83.43M |
| October 05, 2026 | 85.63M |
| October 02, 2026 | 86.73M |
| October 01, 2026 | 92.24M |
| September 30, 2026 | 93.34M |
| September 29, 2026 | 62.73M |
| September 28, 2026 | 67.67M |
| September 25, 2026 | 68.49M |
| September 24, 2026 | 70.96M |
| September 23, 2026 | 74.26M |
| September 22, 2026 | 77.55M |
| September 21, 2026 | 73.43M |
| September 18, 2026 | 73.43M |
| September 17, 2026 | 70.96M |
| September 16, 2026 | 66.02M |
| September 15, 2026 | 66.84M |
| September 14, 2026 | 68.49M |
| September 11, 2026 | 74.26M |
| September 10, 2026 | 76.73M |
| September 09, 2026 | 80.02M |
| September 08, 2026 | 88.25M |
| September 04, 2026 | 89.08M |
| September 03, 2026 | 83.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Precigen, Inc. | 1.723B |
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
| Ionis Pharmaceuticals, Inc. | 4.834B |
| Nektar Therapeutics | 722.92M |
| Rigel Pharmaceuticals, Inc. | 766.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.20M |
| Revenue (Quarterly) | 0.2989M |
| Total Expenses (Quarterly) | 49.50M |
| EPS Diluted (Quarterly) | -0.4989 |
| Gross Profit Margin (Quarterly) | -161.5% |
| Profit Margin (Quarterly) | -16.46K% |
| Earnings Yield | -55.94% |
| Normalized Earnings Yield | -68.98 |